Navigation Links
Favrille Reports First Quarter 2008 Financial Results
Date:5/8/2008

from a patient's tumor. Specifid is currently under clinical investigation in a Phase 3 registration trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to fund operations through the primary endpoint analysis of its Phase 3 clinical registration trial progress and timing of clinical trials for Specifid, including difficulties or delays in development, testing, manufacturing and marketing Specifid or Favrille's other product candidates; whether Favrille's lenders require a letter of credit equal to its outstanding loan balances and the related use of cash; Favrille's ability to obtain additional financing to support its operations; changes in timelines for the availability of data from Favrille's Phase 3 clinical trial; Favrille's ability to obtain marketing approval for Specifid or Favrille's other product candidates and the timing of any such approvals, including whether a clinically meaningful response improvement can serve as the basis for accelerated approval of Specifid and whether it will receive expedited review as a result of the Fast Track designa
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
2. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
3. Favrille Announces $21.1 Million Registered Direct Offering
4. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIO InvestorForum
7. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
8. Favrille CEO to Present at Bear Stearns Healthcare Conference
9. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
10. Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
11. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Tooth decay is an epidemic in American children with 50% ... World Health Organization says that worldwide, 60–90% of ... are the long-term effects of this transmissible infection? , ... oral bacterial imbalance and serious systemic issues like heart disease. ... also 100% preventable? Answer: there has been no way to ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 A ... portable models, from Cole-Parmer is designed to meet ... line includes: , The new Cole-Parmer® MS-3400 ... workhorses in the lab. They ensure a powerful ... plasma specimen separation. Their standard four-place swinging buckets ...
(Date:5/16/2013)... Scientists at the Center for Learning and ... the California -based biopharmaceutical company Magceutics, ... for reversing memory decline in mice with Alzheimer,s Disease. ... improvement in advanced stage AD mice. The study is ... decline for advanced stage AD mice, and is also ...
(Date:5/16/2013)... 16, 2013 BioInformatics LLC New Market ... Stem Cell-Derived Cells: Current and Future Opportunities (13-004) ... suppliers in the primary cells market continues to increase. ... are used most often, how satisfied scientists are with ... and anticipated growth rate. ,  , Additionally, terminally ...
Breaking Biology Technology:Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3Cole-Parmer Offers Enhanced Selection of Centrifuges 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3
... tea, soda and hot chocolate present risk, ... daily caffeine,during pregnancy -- whether from coffee, tea, ... risk of miscarriage, according a new study,by the ... for,the first time, pregnancy-related symptoms of nausea, vomiting ...
... antiviral activity in patients with ... NNRTI-resistant virus ... and Drug,Administration (FDA) has granted accelerated approval to the anti-HIV,medication ... to show antiviral activity in,treatment- experienced adult patients with HIV ...
... 18 Eli Lilly and Company,strongly objects to implications ... company has suppressed results of negative clinical,trials., The ... England Journal of,Medicine (NEJM), cited Prozac and Lilly as ... trial data. Not only was,the Times, story inaccurate when ...
Cached Biology Technology:Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 3Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 4FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 2FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 3FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 4FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 5FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 6FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 7FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 8In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 2In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 4
(Date:5/18/2013)... today at Digestive Disease Week (DDW) explores new discoveries ... of coffee on autoimmune disease and palliative care for ... been associated with reduced risk of fibrosis, a new ... java each month also correlate with lower risk for ... Clinic, Rochester, MN, linked coffee consumption with reduced risk ...
(Date:5/17/2013)... AGA Research Foundation announced a new grant that intends ... microbiota, one of today,s most exciting areas of science, ... Research Awards Panel selected Andrew T. Chan, MD, MPH ... Medical School, Boston, as the 2013 AGA-Elsevier Gut Microbiome ... of funding, commencing in July 2013, to test the ...
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2First Atlanta Science Festival set for 2014 2
... study led by Boston University School of Public Health ... decongestants during their pregnancies are less likely to give ... than 37 weeks, gestation -- is the leading ... but its causes remain largely unknown, said Rohini Hernandez, ...
... 30 August 2010 The coming weeks mark the return ... satisfaction of making new friends and obtaining good test scores ... some school-aged adolescents. The previous decade has witnessed a two-fold ... 12 to 17. 1,2 In an effort ...
... often take communication courses unrelated to their major or ... up with the Library and English Departments to develop ... understand literature searchers and incorporate them into papers and ... Gail R. Nonnecke, Iowa State University faculty from the ...
Cached Biology News:BUSPH study observes link between decongestant use in pregnant women and lower risk of preterm birth 2School-based intervention successfully lowers drinking rates in at risk children 2Teaching communication and information literacy skills 2
NuParaffin Kit Application: Flow Cytometry Reactivity: Human...
Request Info...
...
Highly efficient electroporation solution suitable for transfection of plasmid DNA, oligonucleotides and siRNA. Compatible with all common electroporators....
Biology Products: